BigHat's Milliner platform pairs frontier models with automated lab work, and its first antibody-drug conjugate is now in patients.
The London biotech's Series C values it at $800 million and funds EDEN models aimed at rewriting a patient's cells…
Enveda closed a $311 million Series E led by Catalio to push three clinical-stage medicines deeper into development.
The San Diego drug designer lands a large pharma partner days before asking public investors to fund its pipeline.
The company says its platform can cut the time from a research idea to an investigational new drug filing by…
Aureka closes a $100M Series B to train biological foundation models for AI-driven drug discovery.
The AI biotech startup triples its valuation in eight months with backing from Lilly, Pfizer and Novartis partnerships.